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Abstract
Intrinsic resistance of Plasmodium falciparum is clearly a major determinant of the clinical failure of
antimalarial drugs. However, complex interactions between the host, the parasite and the drug
obscure the ability to define parasite drug resistance in vivo. The in vitro antimalarial drug
susceptibility assay determines ex-vivo growth of parasite in the presence of serial drug
concentrations and, thus, eliminates host effects, such as drug metabolism and immunity. Although
the sensitivity of the parasite to various antimalarials provided by such a test provides an important
indicator of intrinsic parasite susceptibility, there are fundamental methodological issues that
undermine comparison of in vitro susceptibility both between laboratories and within a single
laboratory over time. A network of laboratories is proposed that will agree on the basic
parameters of the in vitro test and associated measures of quality control. The aim of the network
would be to establish baseline values of sensitivity to commonly used antimalarial agents from key
regions of the world, and create a global database, linked to clinical, molecular and pharmacology
databases, to support active surveillance to monitor temporal trends in parasite susceptibility. Such
a network would facilitate the rapid detection of strains with novel antimalarial resistance profiles
and investigate suitable alternative treatments with retained efficacy.
Background
In the last five years, new antimalarial drug combinations
have been deployed rapidly in a wide range of settings.
Most of these combinations contain an artemisinin deriv-
ative. Although the artemisinin derivatives retain excellent
efficacy, the selection of resistance to the artemisinins is
only a matter of time. Since treatment courses are gener-
ally short, the artemisinin component is dependent upon
the partner drug for adequate clinical efficacy. When
resistance to the latter reaches a critical level, the efficacy
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of the ACT falls, and it is no longer a suitable treatment for
malaria. Thus, it is crucial to establish systems for detec-
tion of the earliest possible signs of resistance to both
components of ACTs. Because validated molecular mark-
ers are lacking for resistance to artemisinins and because
effective partner drugs used in ACTs will mask early clini-
cal indicators of resistance, in vitro surveillance will be the
critical surveillance tool for the emergence or artemisinin
resistance.
Longitudinal in vitro analysis of the susceptibility of Plas-
modium falciparum strains to antimalarial drugs has three
important attributes. First, this approach allows the
response of clinical isolates to individual drugs to be
assayed, unmodified by important host factors that influ-
ence drug efficacy in vivo. This capacity is crucial because
it allows surveillance for resistance to both components of
an ACT. Second, the progressive decline in drug sensitivity
of isolates from the same site is likely to be the most sen-
sitive method to identify incipient resistance in the para-
site population [1]. Finally, strains with reduced
antimalarial susceptibilities can then be established in
continuous culture to provide the tools needed to investi-
gate novel molecular mechanisms of resistance and for
tests of susceptibility to other antimalarial agents.
Despite its obvious value, the wide variance associated
with the estimates derived from the in vitro assay makes
the comparison of data between laboratories problematic.
The consortium that met at the Wellcome Trust Sanger
Centre in October 2006 proposed that a network of
regional laboratories should be established with a com-
mon test protocol and quality control methodology. Such
a network would link with other established surveillance
systems, but provide an additional global perspective
within a novel initiative: the World Antimalarial Resist-
ance Network (WARN). The in vitro module of the WARN
database will identify the key parameters that can be
standardized sufficiently to overcome the major factors
responsible for inter- and intra-laboratory variability. This
would minimize the bias between geographically separate
research sites and identify temporal trends that could
reveal the emergence of strains of plasmodia resistant to
the drugs that are now being used widely.
Rationale
The goal of the WARN database is to establish a world-
wide system for collating information on resistance to
antimalarial drugs. Testing for antimalarial in vitro sensi-
tivity phenotypes from diverse endemic regions to drugs
in use or in development is a crucial component of this
network, for the following reasons: (1) the response of a
patient to drug treatment is complex, and (2) reflects host
factors as well as the intrinsic response of the parasites to
the drug. Analysis of the parasite response to the drug in
vitro minimizes host factors, and provides a measure of
fundamental parasite antimalarial sensitivity.
1. The in vitro analysis produces a quantitative estimate of
the effectiveness of the drug on the growth of the parasite.
Longitudinal studies and comparison of the in vitro para-
site responses, within a defined human population can
reveal trends in sensitivity to a particular drug and, thus,
the earliest possible warning of resistance that is develop-
ing in local parasite populations.
2. The introduction of combination therapy for malaria is
a significant advance in antimalarial policy, but when
therapeutic failures are observed, there is no straightfor-
ward way to determine which drug may be responsible. In
vitro analysis allows each component of a combination to
be tested independently.
3. Many different ACTs are currently being introduced or
developed, but some of the long-lived partner drugs are
chemically similar to each other and to drugs in current
use. In vitro analysis of cross-resistance among potential
new drugs is crucial to avoid development or introduction
of drugs to which parasites are already partially or signifi-
cantly resistant.
4. The reemergence of sensitive phenotypes necessitates
the continuation to monitor older therapies that may
have high drug resistance in a given location. As seen with
the studies with chloroquine in Malawi [2], by removing
the drug pressure for an extended period of time, older but
highly effective therapies can once again be used as first
line treatment.
5. Establishment of stable reference lines with known
drug sensitivity profiles in vitro is a key component of the
proposed network.
a. These lines allow verification of phenotypes in more
than one laboratory.
b. Preservation can establish an archive of parasites that
define the baseline for sensitivity to a newly introduced
drug.
Despite considerable efforts, molecular markers of resist-
ance to most components of the ACTs have not yet been
identified. Parasites with verified resistant phenotypes can
provide the samples needed for identification of the
genetic determinants of drug resistance to particular
drugs.Malaria Journal 2007, 6:120 http://www.biomedcentral.com/1475-2875/6/120
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Challenges
Standardization of procedures
The original WHO in vitro micro-technique was devel-
oped by Karl Rieckmann in 1978 to define the minimum
inhibitory concentration (MIC) of malaria parasites from
clinical isolates [3]. In 1979, Desjardins and colleagues [4]
described a modification that measured tritiated hypox-
anthine incorporation and the emphasis of the final esti-
mate of susceptibility shifted to the IC50. The latter,
defined as the concentration of a drug required to inhibit
parasite growth by 50% compared with the same sample
grown without drug, is now the standard measure of anti-
malarial in vitro susceptibility. Subsequent modifications
have proposed alternative methods of quantifying para-
site growth such as ELISA based (e.g. pLDH or HRPII), or
DNA detection (SYBG green I or Pico green) detection.
Numerous variations in the details of these protocols cur-
rently make it impossible to compare these IC50 values
directly from one laboratory to another [5,6]. At the work-
shop in October 2006, a solution to overcome these prob-
lems was suggested that involved the adoption of two
important principles.
First, that the culture system that underlies the in vitro
assay be standardized with agreement on: (1) the culture
medium, (2) the initial haematocrit, (3) the initial % par-
asitaemia, and (4) the duration of parasite-drug contact.
The second major principle is the adoption of standard-
ized quality controls.
Methods
A common set of reference strains whose genotype and
phenotype are known would be used in all laboratories.
The IC50 values for drugs to be assayed would be deter-
mined routinely on these strains and reported in parallel
with the values determined for the experimental isolates.
Reference strains with known sensitivity to many drugs
are available from the MR4 collection [7]and other strains
could be added as they are defined, or as they become rel-
evant to studies in a particular region. The WHO has
actively supported standardization of in vitro tests and has
provided test kits for use in the field [8,9]. To assure drug
quality and appropriate dosing, 96 well microtitre plates
with known concentrations of mefloquine, quinine, chlo-
roquine, dihydroartemisin, artemisinin and monode-
sethylamodiaquine, (the active metabolite of
amodiaquine) have been available. However, many labo-
ratories produce their own plates for assay of these drugs,
and some components of ACTs have not yet become gen-
erally available. The proposed network would assure that
relevant drugs and metabolites, together with specific
advice on the preparation of test plates, were provided to
the regional laboratories. Many of these newer drugs have
limited solubility and lose potency rapidly so prepared
plates do not have a long shelf life. Under these circum-
stances, the inclusion of reference strains in the overall in
vitro assessment will ensure that the drugs used are of
appropriate quality and activity, and that the test plates
are uniformly prepared according to set guidelines. Inclu-
sion of regional or global controls will help to eliminate
laboratory bias, ensure more consistent results, and ena-
ble comparison of data between laboratories worldwide.
Structure
Local and regional networks
The establishment of a network of cooperating laborato-
ries and regional reference laboratories will meet these
requirements most effectively. The centres would conduct
periodic testing on the in vitro plates using control iso-
lates. Centres could also prepare, store and distribute the
reference isolates to ensure the integrity of the strains and
the stability of their phenotypes. There will certainly be
inter-laboratory variation since small differences in cul-
ture conditions will remain, even with a standard proto-
col, but this variation would be minimized and controlled
by comparison of tests on the same reference strains. If a
laboratory reported a reference strain test with a value
lying outside the accepted range of the IC50, this would
trigger a response from the regional centre to address the
problem.
Methods for measuring growth inhibition
In contrast to the agreement that common protocols are
necessary for in vitro culture and in vitro test conditions,
the group proposed that many different methods for
measuring the growth of the parasites were feasible, and
would still produce comparable data. A widely used
method, incorporation of 3H-hypoxanthine into high
molecular weight nucleic acids, has been the "gold stand-
ard" for some time, but ELISA-based methods, fluorescent
dyes that intercalate into DNA and real time PCR are gain-
ing advocates, as well [10-15]. Each method currently
described in the literature has supporters and detractors
and new ones will surely be developed. Some methods are
more adapted to regional centres, and others may be more
appropriate in smaller laboratories. The group proposed
that centres could choose the output method most appro-
priate to their equipment and personnel, and the adop-
tion of reference strains can assure comparability of the
results obtained with the different output assays. The
most important point about the assay method is consist-
ency. When in vitro culture conditions are maintained,
comparable test data are produced, even if different meth-
ods are used to quantify parasite growth. However, once a
method is chosen it is crucial that subsequent longitudi-
nal studies conducted in the same area be done with the
same test system, and any change to a different method be
validated with the previous approach. This consistent
approach will permit detection of small increases in theMalaria Journal 2007, 6:120 http://www.biomedcentral.com/1475-2875/6/120
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IC50 values of local isolates, and can serve as an early indi-
cation of resistance to the drug in question.
Choice of isolates to be assayed
Early detection of resistance to drugs currently in use will
require that baseline parasite chemosensitivity of current
isolates from endemic regions is established, both in
absolute terms as well as the distribution and range of val-
ues expected from a particular laboratory assay. The test-
ing of parasites freshly isolated from patients will provide
key data. However, it is also critical to establish contem-
porary lines in continuous culture, and to freeze aliquots
of those lines for future reference. This will allow puta-
tively resistant isolates to be studied at local and regional
level facilities. Careful verification (or refutation) of resist-
ance in local isolates is, perhaps, the most important role
for in vitro studies [16]. Patients fail treatment for a vari-
ety of reasons, even when the infecting parasites are still
sensitive to the drug: poor drug absorption, atypical
metabolism, the presence of co-infections and many other
factors. These parameters are especially important but
often poorly understood for the newer ACTs, [17-20], and
it is crucial to determine whether parasite resistance to the
treatment is the actual cause of clinical failure. The deter-
mination of the in vitro sensitivity of the putatively resist-
ant parasites is the most direct approach.
In vitro data from retrospective studies of previously cul-
tured parasites can also be an important and useful part of
the proposed database. Archiving of current isolates with
dependable data on their sensitivity to a wide range of
drugs will also allow each region to establish baseline val-
ues and thus to follow more effectively the trends in sen-
sitivity to the drugs in use [1,18,21-23]. Documentation
of rising IC50 values over the original background is a clear
warning of developing resistance. In aggregate, data from
these disparate isolates can provide baseline platforms for
comparison of temporal trends as surveillance is devel-
oped and extended.
Data handling, quality and reporting
The overall database will be created using individual
patient records. The in vitro test for one parasite strain/
one drug constitutes a series of measurements of parasite
growth, over the drug/parasite contact period, in a range
of drug concentrations. Normally, the 8 wells of a 96-well
micro-culture plate are sufficient to generate a dose-
response curve from which the essential output, the IC50,
Output of the raw data from an in vitro experiment Figure 1
Output of the raw data from an in vitro experiment. This is an example of output from tools that will be freely available 
on the in vitro module of the web site.Malaria Journal 2007, 6:120 http://www.biomedcentral.com/1475-2875/6/120
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can be determined. Whatever the method chosen to meas-
ure parasite growth, collection of data into a local elec-
tronic data base will allow the efficient archiving and
analysis of the data for each drug-parasite test. A number
of analysis programmes are available [24] and the in vitro
module of this database will have such a programme on
the web site. Figure 1 shows the output from one such
programme, which includes a display of the input data,
the resulting dose-response curve and the formula for cal-
culating the IC50 value. Key parameters of the graph are
calculated, so that the quality of the data can be readily
assessed. The IC50 (or any other proportional degree of
inhibition, like the IC90) is also calculated using the logis-
tic dose response, using a four-parameter equation includ-
ing the IC50 – Slope, the Emin (lower limit or asymptote)
and the Emax (upper limit or asymptote).
In addition, calculation of the geometric mean of the IC50
values from a group of isolates and the standard deviation
or 95% confidence interval will be readily managed using
the programme on the web. This will facilitate the analysis
of data by individual groups, but the programme will not
automatically enter the data into the central database.
That action will require specific authorization from the
group that has generated the data and from the database
manager. However, this system should allow a straightfor-
ward path for both data and the analysis to be submitted
for entry into the central database. Inclusion of this kind
of information, along with the data and calculations of
the same parameters for the reference strains, determined
in parallel, should permit data from different sites and dif-
ferent times to be compared.
The database would not set a cut off for sensitivity vs.
resistance of the isolates assayed for particular drugs.
These designations have created confusion [25], and it is
clear that even when data are collected in a consistent way,
the IC50 values for a set of strains usually represent a con-
tinuous distribution rather than the bimodal distribution
suggested by the classification. However, by linking data
with in vivo results, pharmacokinetics, and when possi-
ble, molecular markers of resistance, researchers can start
to set limits of sensitivity. However, arbitrary cut offs
applied to in vitro data are probably not useful.
Tools included in the in vitro module of the database will
have software programmes that make analyses of subsets
of the data possible by any user. The database will be
designed so that all entries can be queried with common
algorithims. For example, the inclusion of individual data
would make it possible to query the database to deter-
mine the rates of change in IC50 values for a particular
drug in isolates from different regions. Currently, most of
the information on the speed with which resistance
evolves to particular drugs derives from Southeast Asian
sites [13,26-28]. It is not at all clear how those rates might
predict the spread of resistance in sites with very different
characteristics and levels of transmission [29]. The pro-
posed network will collect the necessary data and the data-
base will collate the information to allow questions of this
kind to be productively addressed.
The database is designed for open access on the web, and
it will be most valuable if data are submitted as rapidly as
they are generated. Access to the tools for data entry and
analysis will be freely available on the web site, and this
will provide an incentive for groups to submit data to the
database manager for inclusion in the database. This
approach will facilitate the preparation for publication of
the data that have been collected by a group, and assure
that the important professional work of in vitro surveil-
lance is rewarded. Although the database will include
information from patient isolates, the entries will be
anonymous, and the linkage to any patient information
will be designed to assure patient anonymity.
Benefits
Rapid identification of putative resistant isolates
In vitro assay of patient isolates and comparison with the
sensitivity of reference strains to the same drugs is still the
most direct way to determine whether parasite resistance
is responsible for an increase in drug treatment failures. If
a decline in clinical efficacy of an ACT is observed, in vitro
testing of patient isolates will be required to determine
whether host factors or an intrinsic decline in parasite sus-
ceptibility underlie the observation [30,31]. The proposed
network must be organized and activated now, so that
baseline sensitivity to the various ACT partner drugs can
be clearly defined. In vitro testing is the only system that
is presently available to provide clear early warning of
impending resistance to the components of ACTs. A net-
work of laboratories that can produce high quality in vitro
data from many different endemic areas and make these
data accessible in an open database can provide the sur-
veillance that is required.
Definition of molecular markers for resistance to ACT 
components
In vitro assays of drug sensitivity to chloroquine and sul-
phadoxine-pyrimethamine and mefloquine have played a
key role in defining the molecular markers responsible for
resistance to these drugs. The genetic changes associated
with resistance were identified by comparison of the gen-
otypes of parasites with sensitive and resistant pheno-
types, but the loci responsible for resistance were
identified long after clinical resistance to the drugs had
risen to unacceptably high levels (reviewed in [13,32-
34]). Definitive molecular markers for drug resistance to
the different artemisinin derivatives being used, or indeed
to any of the partner drugs, except mefloquine, are notMalaria Journal 2007, 6:120 http://www.biomedcentral.com/1475-2875/6/120
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available [19]. Because of the very short half-life of artem-
isinins, they have been paired in combinations with
longer-lived partners for longer drug action and prophy-
laxis against reinfecting parasites. This approach means
that parasites are then exposed in vivo to these partner
drugs alone for an extended period, and selection of resist-
ance to the partner drugs is far more likely than to the
artemisinin. There are already hints that this is occurring
[19,35-37]. Rapid identification of resistance to a long-
lived partner will allow a new partner to be chosen, pro-
tecting the artemisinin component. This assumes, of
course, that there is an active "pipeline" of potential part-
ners available when the need arises.
In vitro identification of a series of parasite lines from nat-
ural isolates stably resistant to artemisinins and to their
partner drugs, lumefantrine, mefloquine, pyronaridine,
piperaquine and amodiaquine is the first step to define
the genetic basis of resistance to each class of drug. Com-
parison of the genomes of these resistant parasites with
related lines that remain sensitive to the drug will allow
genetic differences to be identified and loci responsible
for the resistance to be validated. A reference genome of
the 3D7 P. falciparum is available [38], and single nucle-
otide polymorphisms [39-41], small insertions and dele-
tions [42] and changes in copy number [43] in patient
isolates and strains established from them can now be
compared relatively rapidly with reference genomes. This
whole genome approach readily identified the locus that
is principally responsible for resistance to chloroquine
[44] and this is the most direct approach to identify loci
with associations to resistance to the various components
of ACTs. Molecular markers associated with resistance to
any of the components of ACTs could provide a second
key early warning of the emergence and spread of resist-
ance to these valuable drugs.
Linkage to other modules of the WARN database
The World Antimalarial Resistance Network aims to create
an individual level database containing information on
clinical, in vitro, pharmacokinetic and molecular markers
of antimalarial resistance. The system is described in more
detail in the paper on the clinical module of the database
and on the web site where the prototype database resides
[45]. There will be some instances where both the clinical
outcome of treatment and contemporary determination
of in vitro sensitivity to drugs will be available. Moreover,
the pharmacokinetic response of a patient to the treat-
ment drug may be linked from that module (a sub-set of
the main database), as well. When complementary infor-
mation like this is available on an isolate, the records will
be linked so that pharmacokinetic and pharmacodynamic
information can be correlated. However, the bulk of the
data on in vitro analysis is unlikely to be linked to a par-
ticular patient record. In those cases, individual records
will still be used, and information on the time and place
of collection of the isolate will be included. Molecular
markers of resistance to particular drugs will also be deter-
mined for many of the individual isolates that are tested
for chemosensitivity in vitro, and will be linked, through
the database structure, to the in vitro test results.
Understanding geographic and temporal trends in parasite 
resistance
Currently, in vitro data on antimalarial drug resistance are
available only for a few locations. The absence of regional
information and the lack of coordinated data over a long
time period make it almost impossible to follow trends
that could give early warning that resistance to the antima-
larial drugs in use is emerging. This network and the asso-
ciated database will be a common source of data on the in
vitro response to drugs of parasites from many endemic
areas. The database will provide programmes on the web
site that will facilitate the analysis and presentation of
trends in in vitro sensitivity from all malarial regions and
on a real-time basis. Those who advise policy makers will
then have the tools needed to present a coherent picture
of drug resistance in their country and region. This feature
should make it possible to provide evidence to those
responsible for changing drug policy when increasing
resistance is observed.
Conclusion
The introduction of ACTs has made a dramatic impact on
malaria treatment in many countries [46], and there is
progress in solving the various economic and logistical
problems that have slowed their introduction in some
regions [47]. Currently, these drugs are effective almost
everywhere, but there are already hints that resistance to
artemisinins is emerging [30] and resistance has already
compromised the efficacy of some ACT partner drugs. It is
crucial to quickly devise and activate a comprehensive
plan for monitoring closely ACT drug effectiveness.
WARN sets out to do just that. The clinical components of
the database will provide much needed data on drug effi-
cacy, but the malaria community cannot afford to wait
until clinical failure of these drugs arises. The experience
with chloroquine and sulphadoxine-pyrimethamine is
clear: if action is taken only after clinical failures are com-
mon, it will be too late to save these valuable drugs. The
in vitro network will provide the most sensitive bellwether
of the emergence of resistant parasites: rising IC50 values
of contemporary parasites. Moreover, parasites with drug
resistant phenotypes in vitro are the key to using modern
genomic comparisons to identify the genetic changes that
underlie the resistance. There is no time to waste.Malaria Journal 2007, 6:120 http://www.biomedcentral.com/1475-2875/6/120
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